Natasha Patela,
Truc T. Phama,
Arshiya Banua,
Alex Griffithsb,
Brett M. Patersonc,
George Firth
a,
Alexander Morrellb,
Clíona McMahond,
Nicholas J. Long
e,
James R. Baker
d,
Vijay Chudasama
d and
Michelle T. Ma
*a
aSchool of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas’ Hospital, London, UK. E-mail: michelle.ma@kcl.ac.uk
bLondon Metallomics Facility, King's College London, Franklin Wilkins Building, London, UK
cCentre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia
dDepartment of Chemistry, University College London, Kathleen Lonsdale Building, London, UK
eDepartment of Chemistry, Imperial College London, Molecular Sciences Research Hub, London, UK
First published on 26th August 2025
Mass cytometry with antibodies labelled with stable metal isotopes enables both sensitive imaging and the quantification of protein expression in biological samples. Typically, these specimens are exposed to a panel of labelled antibodies ex vivo, after sample collection. Here, we have developed a rhodium-labelled immunoconjugate of the HER2-targeted therapeutic IgG1 antibody, trastuzumab, and evaluated its in vivo biodistribution using mass cytometry techniques. A Rh3+ complex of a macrobicyclic sarcophagine (sar, 3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane) chelator was appended with a dibromopyridazinedione (DBPD), to produce a novel disulfide bond labelling molecule, “Rh-sar-DBPD”. Rh-sar-DBPD was site-specifically conjugated to trastuzumab via its four native solvent-accessible disulfide bonds, to yield a near homogeneous, well-defined and stable pyridazinedione (PD) immunoconjugate, Rh-sar-PD-trastuzumab, in which four Rh-sar-PD groups were attached per molecule of trastuzumab. Inductively coupled plasma mass spectrometry (ICP-MS) and laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) were then applied to measure 103Rh content, as a proxy for Rh-sar-PD-trastuzumab accumulation, in in vitro and in vivo studies. ICP-MS in vitro studies indicated HER2-mediated uptake of Rh-sar-PD-trastuzumab in HER2-expressing breast cancer cells, with LA-ICP-MS images showing intercellular heterogeneity in Rh-sar-PD-trastuzumab uptake. To study the in vivo biodistribution of Rh-sar-PD-trastuzumab, female NSG mice bearing orthotopic HCC1954 breast cancer tumours were administered the immunoconjugate. Quantitative ICP-MS of 103Rh signal in dissected tissues indicated receptor-specific HER2-mediated uptake in tumours, as well as accumulation in the spleen and liver. Finally, LA-ICP-MS imaging analysis of tumour and ovary tissue sections showed heterogeneous uptake in HER2-expressing HCC1954 tumour cells and follicular granulosa cells of the ovaries, which are known to express growth factor receptors. To the best of our knowledge, this is the first report in which both ICP-MS and LA-ICP-MS have been used on tissue exposed to a metal-tagged antibody in vivo, enabling quantification of the biodistribution of the novel immunoconjugate, Rh-sar-PD-trastuzumab, in a murine model of breast cancer.
Mass cytometry uses IgG antibodies tagged with monoisotopic, non-endogenous transition and lanthanide metal ions to provide information on protein expression. Biological samples are first exposed to a panel of antibodies, with each antibody tagged with a single stable isotope of a metal ion. Individual cells, populations of cells or tissue sections are then analysed by ICP-MS to measure metal content. The metal content serves as a metric for antibody accumulation, and therefore, protein expression. As mass spectrometry can quantitatively measure numerous metals in a single sample, a cocktail of antibodies, each with a unique metal tag, can provide a vast array of “multiplexed” information on protein expression and cell processes, from the single cell to the tissue level. Although novel and potentially useful complexes based on In,2 Te,3 Zr,4 Re and Pt5 have been explored, the most frequently employed commercially available mass cytometry tagging technologies6–8 use:
• polymers of DTPA (diethylenetriamine pentaacetic acid) and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) chelators complexed to stable, single isotopes of metal ions, including lanthanide ions, and
• maleimide–thiol bioconjugation chemistry to attach the polymeric derivatives to reduced solvent-accessible disulfide bonds in an IgG. In IgG1 antibodies, eight reduced cysteine residues are available for attachment to these Ln-DOTA polymer tags, resulting in high degrees of metal loading or heterogeneous mixtures when the target has an average loading of less than eight.
In combination, LA-ICP-MS and mass cytometry antibodies have been used for ex vivo immunohistochemical profiling of protein expression9–13 (and other biomolecules, e.g. mRNA14) in tissue samples acquired from patients and animal models. Tissue sections are exposed to a panel of metal-tagged IgG antibodies (or other vectors) only after collection of samples from the in vivo environment (Fig. 1a). The information obtained is similar to that acquired using multiplexed fluorescently-tagged proteins for fluorescence microscopy studies. Critically, imaging mass cytometry enables greater multiplexing (≥40 channels) and lower background interference.1
Despite the adoption of mass cytometry and LA-ICP-MS to measure protein receptor expression, there have only been a limited number of ICP-MS and LA-ICP-MS imaging studies on the in vivo biodistribution of metal-tagged biomolecules (although not antibodies), in which the metal-tagged biomolecule is first administered to an animal, prior to tissue processing and LA-ICP-MS imaging analysis of tissue samples (Fig. 1b). Administration of a novel tellurium-tagged derivative of phenylalanine amino acid, TePhe, to a tumour-bearing mouse enabled highly resolved and specific LA-ICP-MS imaging of protein translation and synthesis pathways by mapping the distribution of 130Te in tissue sections.15 The biodistributions of a range of nanoparticles have also been studied in vivo using ICP-MS on tissue digests, e.g., Pd-labelled PLGA drug delivery agents,16 Au dual diagnostic/therapeutic nanoparticles,17,18 and metal-labelled peptides and proteins.19–22
Our research aims to develop new chemical platforms that enable quantitative imaging and mapping of peptide and antibody biodistribution in vivo – to date, we have exclusively used radioactive metal ions for nuclear medicine applications.23–27 Other radiopharmaceutical scientists have substituted radioactive metal ions for stable isotopes in receptor-targeted peptides and proteins, and applied these isotopologues to interrogate the stability, biodistribution, metabolism and excretion of these bioconjugates in vivo.21 Understanding the pharmacokinetics of radiotracers is important to not only establish diagnostic and therapeutic efficacy, but also determine blood clearance times, excretion routes and radiation dose (and concomitant toxicity) to non-target tissues and organs.21
For example, 90Y-labelled β−-emitting antibodies were amongst the first receptor-targeted systemic radiotherapies to undergo clinical evaluation. To complement these innovations, antibody fragments were labelled with the stable isotope, 89Y, allowing ICP-MS quantification of 89Y excretion in urine.22 More recently, the radiotracers 177Lu-PSMA-617 and 161Tb-PSMA-617 have demonstrated efficacy in systemic radiotherapy of prostate cancer. ICP-MS in combination with the non-radioactive derivatives, 175Lu-PSMA-617 and 159Tb-PSMA-617, enabled quantification of the accumulation of these compounds in target prostate cancer tissue and non-target tissue, including excretory organs.19 Indeed, side-by-side γ-counting (using radioactive analogues) and ICP-MS studies yielded near-identical data. The in vivo plasma behaviours of disease-targeted peptides labelled with naturally abundant, non-radioactive isotopes of Ga and In (as proxies of radioactive 68Ga and 111In) have also been interrogated using ICP-MS. HPLC-ICP-MS studies of serum samples from rats administered these probes indicated distinct metabolic profiles of the Ga-labelled peptides compared to their In-labelled analogues, including transchelation of Ga3+ but not In3+ from the peptide to transferrin protein in blood plasma.20
Whilst these studies utilise ICP-MS only, the outcomes highlight that similar quantitative and qualitative ICP-MS information can be obtained using bioconjugates of non-radioactive metals in place of radioactive analogues. Here, we turn our attention to the use of a stable metal isotope, 103Rh, for tagging and mapping the biodistribution of an antibody at the whole body level, using not only ICP-MS, but LA-ICP-MS to provide high-resolution images of antibody accumulation in specific tissue. To the best of our knowledge, this is the first report in which mass cytometry imaging has been undertaken using tissue exposed to a metal-tagged antibody in vivo, and the first report in which the organ and tissue biodistribution of an antibody has been quantified using ICP-MS. We postulate that ICP-MS has applications in quantifying the biodistribution of new antibody-based drugs, revealing patterns of antibody accumulation in different tissue compartments, interrogating heterogeneity in antibody uptake and yielding valuable information on in vivo receptor expression.
(i) A Rh3+ complex of a (NH2)2sar chelator. Derivatives of a hexaazamacrobicyclic chelator, 3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane, commonly known as “sarcophagine” (sar), can chelate a range of metal ions,30 and are thus well suited to incorporating metal tags into proteins for the purposes of quantitative in vivo mapping and tissue imaging.24,31 Furthermore, low-spin d6 Rh3+, Ir3+ and Pt4+ ions form thermodynamically and kinetically stable complexes with sar, potentially expanding the mass cytometry chemical toolbox.30,32 Additionally, Rh possesses a single, stable naturally abundant isotope, 103Rh. Nature does not use Rh for biological functions; negligible amounts of endogenous 103Rh were expected in in vitro or in vivo studies described herein.
(ii) A dibromopyridazinedione (DBPD) functional group.33–37 The dibromopyridazinedione group reacts specifically with the thiols of a reduced disulfide bond, thus re-bridging the cysteine residues and enabling attachment of cargo to the biomolecule. Dithiol-substituted pyridazinedione (PD) bioconjugates, formed from the reaction of dibromopyridazinediones with reduced disulfides, are highly stable in blood serum, which is in contrast to the commonly-employed maleimide–thiol based bioconjugates, which are prone to retro-Michael reactions and ultimately the premature release of cargo or tags under in vivo conditions, compromising quantifiability of antibody distribution.38–41
![]() | ||
Scheme 1 Amide coupling reaction of the sarcophagine complex [Rh((NH2)2sar)]3+ (1) with a dibromopyridazinedione acid derivative (2) to form Rh-sar-DBPD (3). |
The reaction of Rh-sar-DBPD (3) with trastuzumab was optimized to achieve a payload to antibody (PAR) ratio of 4 (Table S1). The four solvent-accessible interstrand disulfide bonds of trastuzumab were reduced with mild reducing agent TCEP (tris(2-carboxyethyl)phosphine). Following removal of TCEP, Rh-sar-DBPD (10 equiv.) was reacted with the liberated cysteines (Scheme 2) by incubation in aqueous borate buffered saline (pH 8) at 37 °C for 3 h under constant agitation, to produce the desired pyridazinedione (PD) conjugate. Following buffer exchange into phosphate buffered saline (PBS) solution and purification using size-exclusion chromatography and spin filtration, the resulting Rh-sar-PD-trastuzumab conjugate was characterised by SDS-PAGE, UV-Vis spectroscopy and ESI-MS.
![]() | ||
Scheme 2 Antibody bioconjugation reaction in which the four interstrand disulfide bridges of trastuzumab IgG1 antibody are reduced, followed by re-bridging with Rh-sar-DBPD (3). |
As expected, SDS-PAGE analysis of trastuzumab under TCEP-based reducing conditions showed the presence of separate heavy and light chains under the denaturing analysis conditions (Fig. 2a, lane 3) compared to the unmodified antibody (lane 2). For the new Rh-sar-PD-trastuzumab bioconjugate, the two major products observed by SDS-PAGE corresponded to the “full antibody” conjugate, in which the PD groups bridged the interchain thiols at the hinge region, and the “half antibody” conjugate, in which the PD groups bridged intrachain thiols at the hinge region (Fig. 2a, lane 4). The full antibody re-bridging pattern resembles the native covalent linkages of unmodified trastuzumab. The half antibody fragment (comprising of a heavy chain and a light chain) arises because of non-native covalent linkages; this is commonly observed in dicysteine re-bridging reactions.42,43 Both re-bridging patterns result in an overall loading of four Rh-sar modules per full antibody. In physiological solutions (e.g. aqueous saline, PBS) and biological milieu (e.g. blood pool), two half antibody fragments are held together by non-covalent interactions in the Fc region. There is little to indicate that this “half antibody” product, containing intrachain-bridged thiols at the hinge region, would perform poorer in vivo with respect to HER2 and Fc receptor binding.44 Only very small amounts of heavy chain and light chain fragments were observed by SDS-PAGE; these were only visible when the SDS-PAGE gel was loaded with a highly concentrated sample. Our previous studies using dibromomaleimide derivatives of sarcophagine complexes achieved the same site-specificity, but led to higher observable amounts of heavy chain and light chain fragments in SDS-PAGE analyses,24 indicating the superior ability of the dibromopyridazinedione to produce minimal byproducts.
![]() | ||
Fig. 2 (a) SDS-PAGE of trastuzumab and the new immunoconjugate, Rh-sar-PD-trastuzumab; (b) UV-Vis spectra of Rh-sar-PD-trastuzumab, alongside native trastuzumab. Full gels are included in Fig. S5. |
Dithiol-substituted pyridazinediones exhibit a distinct λmax absorbance band at 335 nm (ε335 = 9100 M−1 cm−1), and the UV-Vis properties of trastuzumab are well-characterized (ε280 = 215000 M−1 cm−1). UV-Vis spectroscopic analysis of the ratio of the 280 nm and 335 nm absorbance values was used to determine an average loading of 4.06 Rh-sar-PD linkages per antibody (Fig. 2b).
ESI-MS analysis was consistent with the SDS-PAGE and UV-Vis measurements. Deconvoluted ESI-MS spectra of the bioconjugate product revealed a relatively broad envelope of signals, corresponding to the presence of the “half antibody” species with the expected two Rh-sar-PD complexes per fragment, alongside the “full antibody” species with the expected four Rh-sar-PD complexes per fragment (Table 1 and Fig. S4). Experimental values fall with 12 a.m.u. of the calculated values. We also observed additional deconvoluted signals at higher m/z ratios for both half and full antibody [M]+ species (Fig. S4), leading to an envelope of multiple species. This “envelope” was significantly broader than that observed for unmodified trastuzumab and similarly prepared and characterized alkyne–trastuzumab immunoconjugates.43,44 We attribute this envelope to gas-phase adducts. For example, there is a strong “half-antibody” conjugate with a m/z signal of [M + 41]+, which we postulate is an acetonitrile adduct. We have previously observed this phenomenon with other sarcophagine derivatives.24
Half antibody conjugate | m/z (calculated) | m/z (observed) |
---|---|---|
Rh-sar-PD-trastuzumab | ||
Half antibody + 2 Rh-sar tags | 73![]() |
73![]() ![]() |
Full antibody + 4 Rh-sar tags | 147![]() |
147![]() |
The ESI-MS signal corresponding to the “half antibody” had the highest intensity. The “full antibody” was observed at a much lower signal intensity. This is a common feature of such immunoconjugates because the smaller fragments are almost always detected with significantly higher relative intensity,24,43 likely due to mass spectrometric desolvation, ionisation and ion transport effects.45
The combination of SDS-PAGE, UV-Vis spectroscopic and ESI-MS analysis indicates the successful preparation of a highly homogeneous bioconjugate, in which each trastuzumab molecule contains an average of four Rh-sar-PD complexes site-specifically attached at each of the four native interchain disulfide groups of trastuzumab.
Preliminary LA-ICP-MS 103Rh imaging was undertaken using Rh-sar-PD-trastuzumab to assess the sensitivity of Rh-sar-PD-trastuzumab for detecting differential HER2 expression in single HER2-positive HCC1954 cells and HER2-negative MDA-MB-231 cells. In side-by-side experiments, the immunoconjugate was incubated with either HCC1954 cells (with and without excess trastuzumab as a blocking agent) or MDA-MB-231 cells. After washing and fixing, cells were imaged using a bright field light microscope and LA-ICP-MS for 103Rh signal at a resolution of 8 μm. The spatial distribution of the 103Rh signal corresponded with the breast cancer cells. Quantification of 103Rh LA-ICP-MS images indicated that a significantly higher average concentration of 103Rh was associated with HCC1954 cells compared with MDA-MB-231 cells (Fig. 3b). For HCC1954 cells, the average 103Rh concentration measured 3.00 ± 0.68 counts per pixel (n = 21); for MDA-MB-231 cells the average 103Rh concentration measured 1.51 ± 0.49 counts per pixel (n = 10, mean difference = 1.49, p < 0.0001) (Fig. 3c). Additionally, HCC1954 cells incubated with Rh-sar-PD-trastuzumab co-administered with a blocking dose of trastuzumab showed a decreased average 103Rh concentration (2.26 ± 0.52 counts per pixel, n = 13) compared with that of HCC1954 cells administered Rh-sar-PD-trastuzumab only (mean difference = 0.74, p = 0.005). Furthermore, in HCC1954 and MDA-MB-231 cells, there was a significant “spread” in the average 103Rh concentration measured for each cell. This is possibly due to intercellular heterogeneity in HER2 expression or intercellular heterogeneity in immunoconjugate binding.
Potassium signal, specifically 39K, is often used to delineate cells in LA-ICP-MS studies. In a separate experiment, the distributions of both 103Rh and 39K were simultaneously measured in HCC1954 cells treated with Rh-sar-PD-trastuzumab. As expected, the spatial distribution of 39K signal correlated with 103Rh signal (Fig. S6).
These in vitro studies indicated that (LA-)ICP-MS in combination with a new Rh-sar appended trastuzumab immunoconjugate can provide information on the relative expression of HER2 in both bulk tissue culture, and also at the single cell level, with data correlating with known HER2 expression levels in HCC1954 and MDA-MB-231 breast cancer cells.46 We note that analysis of a larger population of these cells would enable more robust quantification of antibody uptake as a proxy for HER2 expression. Similar data could also be obtained using single cell ICP-MS analyses.
The measured 103Rh content was 1.67 ± 0.21%ID g−1 in HER2-expressing tumour tissue (Fig. 4 and Table S6). The 103Rh content decreased in tumours of mice pre-administered with excess trastuzumab: in this “blocked” group, tumour 103Rh content measured 0.48 ± 0.19%ID g−1 (mean difference = 1.19 ± 0.21%ID g−1, p = 0.0002), consistent with trastuzumab blocking HER2-mediated uptake of Rh-sar-PD-trastuzumab immunoconjugate.
Statistically significant “blocking” effects were also observed in ovarian, heart, stomach and large intestine tissues, and blood (Fig. 4 and Table S6). We attributed some Rh-sar-PD-trastuzumab uptake, alongside trastuzumab “blocking” effects in heart, gastrointestinal and blood samples, to reactivity between the humanised Fc domain of Rh-sar-PD-trastuzumab/trastuzumab and murine Fc-receptors. The Fc domains of humanised IgG1 therapeutic antibodies have affinity for murine Fc-receptors, including (i) FcγR of effector immune cells such as macrophages and neutrophils that circulate in the blood and also reside in the spleen, and (ii) FcRn, expressed in the gastrointestinal epithelium, vascular endothelium, liver and immune cells.47,48 The immune deficient NSG mice used in this study lack B cells, and therefore also lack normal endogenous circulating murine immunoglobulins that would normally compete with trastuzumab/Rh-sar-PD-trastuzumab for Fc-receptors in immunocompetent mice. It is likely that the pre-administered dose of excess, competing trastuzumab reduces binding of the Fc domain of Rh-sar-PD-trastuzumab to murine FcγR and FcRn, leading to lower concentrations in compartments known to contain murine FcγR and FcRn Fc-receptors, such as the blood pool and gastrointestinal tract.
For both groups of mice, there were also significant amounts of 103Rh measured in organs in which IgG antibodies are known to residualise, specifically the spleen and liver. Effector immune cells, which express Fc-receptors, are also well-documented to reside in the spleen and liver, and the observed Rh-sar-PD-trastuzumab biodistribution patterns are consistent with prior studies reporting radiolabelled trastuzumab in mouse models.24,25,49
Administration of trastuzumab (1 mg) 2 days prior to Rh-sar-PD-trastuzumab (500 μg) resulted in decreased 103Rh content in ovarian tissue, from 0.48 ± 0.07%ID g−1 to 0.20 ± 0.09%ID g−1 (mean difference = 0.28 ± 0.21%ID g−1, p = 0.003). This suggests that Rh-sar-PD-trastuzumab uptake in ovarian tissue is mediated by receptor-specific interactions. We note that human ovarian and gastrointestinal tract tissue are known to express HER2,50 and in mice, the equivalent neu receptor is also expressed at low levels in these organs.51,52 However, trastuzumab does not exhibit affinity/cross-reactivity for murine neu receptors.53 It is therefore unlikely that the blocking effects observed in healthy murine tissue are a result of interactions between the Fv domain of trastuzumab/Rh-sar-PD-trastuzumab and murine neu receptor. We postulate that 103Rh accumulation in ovarian tissue is due to interactions between trastuzumab/Rh-sar-PD-trastuzumab and other murine growth factor receptors (vide infra).
For mice treated with either Rh-sar-PD-trastuzumab or Rh-sar-PD-trastuzumab + blocking trastuzumab, LA-ICP-MS imaging of tumour sections revealed 103Rh signal in tumour tissue, but negligible signal in surrounding adipose or necrotic/apoptotic/acellular tissue. Consistent with ICP-MS biodistribution data, 103Rh signal for the tumour section from the group administered Rh-sar-PD-trastuzumab showed higher 103Rh signal intensity compared to the group co-administered a blocking dose of trastuzumab. These data are consistent with high HER2 specificity of the Rh-sar-PD-trastuzumab immunoconjugate.
Additionally, 103Rh signal in tumour tissue was heterogeneous. Quantification of selected areas in these tumour sections demonstrated this. For a tumour section of a mouse administered Rh-sar-PD-trastuzumab only, 103Rh signal measured up to 100 counts per pixel in one area of tumour section, but more typically between 40–46 counts per pixel in other delineated areas (Fig. S7). Although lower 103Rh values were observed for a tumour section of a mouse administered Rh-sar-PD-trastuzumab + blocking trastuzumab, 103Rh signal was similarly heterogeneous, with uptake measuring up to 30 counts per pixel in one area of tumour, but as low as 9 counts per pixel in an alternately delineated area (Fig. S8).
To validate HER2 expression patterns in the tumour correlated with 103Rh signal, immunohistochemistry (IHC) analysis was undertaken on a contiguous tumour section from a mouse treated with Rh-sar-PD-trastuzumab. Here, an anti-HER2 primary antibody that binds to a HER2 epitope distinct from that of trastuzumab was used to treat tumour sections,54 prior to staining protocols (with a secondary antibody) including counterstaining with haematoxylin and finally, imaging. IHC (Fig. 5) shows that (i) orthotopic HCC1954 tumours indeed express HER2, (ii) HER2 expression is heterogeneous and (ii) in contiguous sections, HER2 expression, as measured by IHC, spatially correlates with 103Rh signal, as measured by LA-ICP-MS using Rh-sar-PD-trastuzumab.
Monoclonal therapeutic IgG antibodies, including trastuzumab, are known to exhibit heterogeneous intratumoral and intertumoral uptake in diseased tissue, either as a result of poor tissue perfusion or heterogeneous target receptor expression.55–57 In breast cancer, this heterogeneity has been associated with resistance to antibody therapies.28 The ability to quantify and image in vivo heterogeneous distribution of a therapeutic antibody using elemental mass spectrometry potentially enables insight into the cause of differences in immunotherapy outcomes.
Sections of muscle, which do not express HER2 or its murine-equivalent, the neu receptor, showed negligible Rh-sar-PD-trastuzumab uptake, with a maximum 103Rh intensity of 1 count.
LA-ICP-MS images of ovarian sections revealed an interesting distribution of 103Rh signal, prompting us to closely compare 103Rh LA-ICP-MS images with ovarian structures in H&E images. Classification of ovarian follicles is complex.58–61 We therefore confined ourselves to basic classifications of the mouse ovary58,59 – that is, identifying follicle structures, oocytes, granulosa cells of follicles, corpus luteum and vasculature.
103Rh signal was coincident with ovarian granulosa cells (GC), which are contained within developing ovarian follicles (F) and surround the oocyte (Oo, colloquially known as the “egg”) (Fig. 6). Importantly, granulosa cells express growth factors and growth factor receptors (including human HER2/murine neu receptors, amongst other members of the epidermal growth factor receptor family).51,62–64 During follicle development and maturation, granulosa cells surrounding the oocyte expand, and the interplay of sex hormones with growth factors and growth factor receptors stimulates oocyte development prior to ovulation. After ovulation, where the oocyte is released from the ovary, the corpus luteum (CL) develops from the remains of the follicle. The corpus luteum produces hormones to support pregnancy; in the absence of pregnancy, the corpus luteum decays.
In H&E images of ovarian sections, follicles at various development stages were identified, including immature follicles without granulosa cells, maturing follicles with significant granulosa cell numbers, and empty follicles (EF). Corpus luteum structures were also observed. Quantification of LA-ICP-MS images (Fig. 6 and S9) revealed the presence of 103Rh signal/Rh-sar-PD-trastuzumab accumulation in granulosa cells (33–59 counts per pixel) and corpus luteum structures (33–41 counts per pixel) but lower amounts in oocytes (17–26 counts per pixel) and immature follicles (9–13 counts per pixel).
Although it is unlikely that Rh-sar-PD-trastuzumab binds to neu receptors expressed in murine granulosa cells,53 we postulate that there is some cross-reactivity between Rh-sar-PD-trastuzumab and other murine growth factor receptors of granulosa cells. This is consistent with reports that murine granulosa cells (including differentiated granulosa cells in mature follicles), but not oocytes, express growth factor receptors.51 It is also possible that 103Rh signal is a result of Rh-sar-PD-trastuzumab binding to Fc-receptors of granulosa cells, however there is little known about Fc-receptor expression in follicle development.
These studies highlight the utility of LA-ICP-MS imaging in revealing the off-target accumulation of antibody therapies, and potential cross-reactivity between antibody therapies and non-target receptors, such as growth factor receptors in reproductive organs. Such insights are critical in understanding the safety profile of antibody therapies.
LA-ICP-MS images were also acquired of the uterine horn. Whilst the intensity of 103Rh signal in sections of the uterine horn was significantly lower than that of granulosa cells of ovarian follicles, there was still some appreciable signal, consistent with both ICP-MS data, and prior studies describing FcRn expression in uterine tissue, predominantly on epithelial tissue.65
At the initiation of this project, we specified several criteria of a desired immunoconjugate, to enable accurate and reliable mass spectrometric analyses:
(i) First, the immunoconjugate needed to be highly stable in vivo so that quantification and imaging of 103Rh signal reflected the distribution of the trastuzumab immunoconjugate, rather than dissociated metal ion or metal complex. The combination of sarcophagine chemistry and dibromopyridazinedione chemistry ensured the formation of a highly stable immunoconjugate.
(ii) Second, the trastuzumab bioconjugation reaction needed to provide a highly homogeneous product, with reproducible site-specific attachment of cargo to the antibody. Immunoconjugates consisting of heterogeneous product mixtures often demonstrate reduced affinity for target receptors or undesirable biodistribution properties.49,66,67 In this study, SDS-PAGE, UV-Vis spectroscopy and ESI-MS analyses demonstrated that Rh-sar-PD-trastuzumab consisted of a homogeneous product, in which four Rh-sar-PD motifs site-specifically bridged at the native interstrand disulfide bonds of the antibody.
(iii) Third, it was highly desired that our trastuzumab immunoconjugate closely mimicked the unmodified trastuzumab, so that biological results from mass spectrometry analyses were relevant in the context of trastuzumab therapies. Existing mass cytometry immunoconjugates contain polymers of DOTA or DTPA complexes: whilst these polymers maximise mass spectrometric signal, it is possible that in vivo, the presence of multiple chains of metal complex polymers would influence the biodistribution. Here, only four Rh-sar motifs were attached per molecule of trastuzumab antibody. This provided sufficient sensitivity to enable not only ICP-MS quantification and LA-ICP-MS imaging of Rh-sar-PD-trastuzumab in tumours, but also mapping of Rh-sar-PD-trastuzumab accumulation in other tissues, providing information on the biodistribution of trastuzumab itself in vivo. Additionally, having a defined payload of four 103Rh atoms per antibody, rather than a polymer with variability in payload number, could enable more accurate quantification of antibody accumulation in tissue and/or receptor expression in tissue.
Currently, whole body quantification of antibody biodistribution can be undertaken with radioactive isotopes and either PET or SPECT imaging (depending on the radioisotope), and/or radioactivity counting of organs ex vivo.23–25,49 Molecular imaging of tissue or cellular structures using antibody derivatives is typically achieved using optical methods, including fluorescence imaging. Here, we have demonstrated that immunoconjugates such as Rh-sar-PD-trastuzumab are well-poised to enable both quantitative biodistribution and highly resolved molecular imaging at the tissue and cellular level. LA-ICP-MS enabled insight into the heterogeneous breast cancer cell uptake of Rh-sar-PD-trastuzumab in vitro and uptake in HER2-positive HCC1954 breast cancer tumours, and for the first time, in developing ovarian follicles in vivo.
Immunoconjugates containing stable metal isotope labels have had extraordinary impact in ICP-MS and LA-ICP-MS mass cytometry platform technologies. We postulate that the immunoconjugates disclosed in this manuscript, as well as derivatives thereof, could have further utility in an in vivo setting, which could lead to new applications in the biomedical research realm, and enable in vivo multiplexing for both ICP-MS biodistribution and LA-ICP-MS imaging analyses.
Supplementary information: details on experimental methods, characterisation data and techniques (NMR, MS, (LA-)ICP-MS) and additional images and spectra. See DOI: https://doi.org/10.1039/d5qi00731c.
This journal is © the Partner Organisations 2025 |